Rafael Holdings Inc
RFL
$2.37
Closing
▲4.41%
1D
▲29.51%
YTD
RFL
BBG00J3YYSB9
Market cap
$58.56M
52 week high
$2.42
52 week low
$1.29
Volume
33,875
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $6.99/month
Market cap
$58.56M
Analysts' Rating
-
Price Target (Mean)
0.00
Total Analysts
0
P/E
Operating Margin
-27726.49%
Beta
1.06
Revenue Growth
373.24%
52 week high
$2.42
52 week low
$1.29
Div. Yield
%
EPS Growth
0.00
Company Profile
Rafael Holdings, Inc. is a holding company with interests in clinical and early-stage pharmaceutical companies. Its segments include Healthcare, Infusion Technology and Real Estate. The Healthcare segment holds interest in LipoMedix Pharmaceuticals Ltd. (LipoMedix), Barer Institute Inc. (Barer), Cornerstone Pharmaceuticals, Inc. (Cornerstone) and Rafael Medical Devices, LLC. The Real Estate segment consists of the Company’s real estate holdings, which is comprised of a portion of a commercial building in Israel. The Infusion Technology segment holds interest in Day Three Labs, Inc. LipoMedix is a clinical-stage pharmaceutical company. Rafael Medical Devices, LLC, an orthopedic-focused medical device company. Cornerstone Pharmaceuticals, Inc. is a cancer metabolism-based therapeutics company. Cyclo Therapeutics Inc. develops Trappsol Cyclo, which is being evaluated in clinical trials for the treatment of Niemann-Pick Disease Type C1 (NPC).
